We are live on
!
Find out more
CM
CM Management Portfolio holdings
AUM
$120M
1-Year Est. Return
37.12%
This Fund
S&P 500
This Quarter
Est. Return
+16.31%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$26.7M
(+25%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
9.95%
Top 10 Holdings %
Top 10 Hldgs %
35.95%
Holding
101
New
21
Increased
28
Reduced
9
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FOLD
Amicus Therapeutics
FOLD
|
+$5.57M |
| 2 |
Alico
ALCO
|
+$2.28M |
| 3 |
Elicio Therapeutics
ELTX
|
+$1.81M |
| 4 |
Exelixis
EXEL
|
+$1.81M |
| 5 |
Merck
MRK
|
+$1.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aterian
ATER
|
+$7.86M |
| 2 |
Aviat Networks
AVNW
|
+$3.95M |
| 3 |
ClearPoint Neuro
CLPT
|
+$3.34M |
| 4 |
Intel
INTC
|
+$2.49M |
| 5 |
Gilead Sciences
GILD
|
+$1.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 40.52% |
| 2 | Financials | 13.92% |
| 3 | Technology | 12.04% |
| 4 | Energy | 10.02% |
| 5 | Materials | 6.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Prudential Financial
PRU
$41.4B
| $1.09M | 0.81% |
+12,000
| New | +$1.03M |
|
|
PRTK
52
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.06M | 0.79% |
150,000
+115,000
| +329% | +$828K |
|
|
VTLE
53
DELISTED
Vital Energy
VTLE
| $1.05M | 0.78% |
35,000
| – | – |
|
54
IAMGOLD
IAG
$8.17B
| $1.04M | 0.78% |
350,000
+150,000
| +75% | +$496K |
|
55
Cytosorbents Corp
CTSO
$22.6M
| $1.04M | 0.77% |
+120,000
| New | +$1.14M |
|
56
Theravance Biopharma
TBPH
$877M
| $1.02M | 0.76% |
+50,000
| New | +$950K |
|
57
Nektar Therapeutics
NKTR
$2.31B
| $1M | 0.74% |
3,333
+1,000
| +43% | +$311K |
|
58
ACNB Corp
ACNB
$617M
| $996K | 0.74% |
+34,000
| New | +$952K |
|
59
VYNE Therapeutics
VYNE
$25.4M
| $984K | 0.73% |
7,986
-961
| -11% | -$139K |
|
|
SPPI
60
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $978K | 0.73% |
300,000
+50,000
| +20% | +$179K |
|
|
BCEL
61
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $920K | 0.68% |
60,000
| – | – |
|
62
Smith Micro Software
SMSI
$14.5M
| $881K | 0.65% |
4,000
-1,000
| -20% | -$264K |
|
|
CSOD
63
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $872K | 0.65% |
+20,000
| New | +$921K |
|
64
MGIC Investment
MTG
$6.23B
| $831K | 0.62% |
+60,000
| New | +$765K |
|
65
Heron Therapeutics
HRTX
$89.1M
| $811K | 0.6% |
50,000
+35,000
| +233% | +$624K |
|
66
Eledon Pharmaceuticals
ELDN
$314M
| $803K | 0.6% |
+75,000
| New | +$1.13M |
|
67
Travere Therapeutics
TVTX
$5.27B
| $799K | 0.59% |
32,000
| – | – |
|
|
CBAY
68
DELISTED
Cymabay Therapeutics
CBAY
| $681K | 0.51% |
+150,000
| New | +$807K |
|
|
FLXN
69
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $671K | 0.5% |
75,000
| – | – |
|
70
Plains GP Holdings
PAGP
$5.07B
| $658K | 0.49% |
70,000
+45,000
| +180% | +$420K |
|
71
1st Source
SRCE
$2.01B
| $571K | 0.42% |
12,000
| – | – |
|
72
Preformed Line Products
PLPC
$1.6B
| $550K | 0.41% |
8,000
+2,830
| +55% | +$198K |
|
|
HGEN
73
DELISTED
HUMANIGEN, INC.
HGEN
| $478K | 0.36% |
25,000
-15,000
| -38% | -$274K |
|
74
EQT Corp
EQT
$31B
| $465K | 0.35% |
+25,000
| New | +$435K |
|
|
CTRA
75
DELISTED
Coterra Energy
CTRA
| $376K | 0.28% |
+20,000
| New | +$368K |
|
Similar funds
AA
CC
DG
ACM
WAG
YMRC
IW
BCWM
CM Management's Q1 2021 Portfolio in Review
As of Q1 2021, CM Management held 101 positions worth $135M, up 25% from $108M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
CM Management deployed $13.4M of net new capital in Q1 2021, opening 21 new positions and adding to 28 existing holdings. Its largest new stake was Elicio Therapeutics: 9,375 shares worth $1.69M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 37% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Aterian, an estimated $7.86M trimmed.
- CM Management's largest Q1 2021 buy was Elicio Therapeutics: 9,375 shares worth $1.69M.
- CM Management added most to Amicus Therapeutics in Q1 2021, an estimated $5.57M increase.
- CM Management's biggest Q1 2021 reduction was Aterian, cutting an estimated $7.86M.
- CM Management fully exited Aviat Networks in Q1 2021, selling an estimated $3.95M.
- CM Management's ten largest holdings make up 36% of its $135M portfolio in Q1 2021.
- CM Management opened 21 new positions and closed 20 in Q1 2021.
- CM Management's portfolio value rose 25% quarter-over-quarter to $135M.
Based on CM Management's 13F filing for Q1 2021, filed 12 May 2021.